



IASLC 17TH WORLD CONFERENCE ON LUNG CANCER

DECEMBER 4-7, 2016 VIENNA, AUSTRIA

Non-Invasive LuCED® Test for Endobronchial Dysplasia, Enabling Chemoprevention Therapy with Drugs Such as lloprost Meyer, Katdare, Presley, Wilbur, Steinhauer, Liang, Zulueta, Keith, Miller, Franklin, Yang, Hayenga,

Nelson





IASLC 17TH WORLD CONFERENCE ON LUNG CANCER

DECEMBER 4-7, 2016 VIENNA, AUSTRIA

VisionGate Produces the LuCED Test

The presenter is the CMO of VisionGate who receives compensation and owns stock





Chemoprevention Dilemma


- Iloprost reverses lung dysplasia to prevent precursor lesions from progressing to a malignant state¹
- Endobronchial dysplasia is not detectable by LDCT
- Non-invasive triage for dysplastic lesions cannot be managed with current methods

I. Keith et. al. Oral lloprost Improves Endobronchial Dysplasia in Former Smokers. *Cancer Prevention Research*. 2011;4(6):793-802.





Dysplasia Detection with LuCED



Images of Cell Sections as Rendered by the Cell-CT

Cell-Based Dysplasia Classifiers

- LuCED detects cell morphometric bio-signatures
- Cell transformation in carcinogenesis is marked in defined steps
- Hypothesis:
 - Cell classifiers may be trained to differentially detect dysplasia





Differential Cell Classification

Dysplasia Classifier


Dysplasia vs. Cancer/Normal Training:

- 88,137 Normal/Cancer
- 686 Dysplasia


Cancer Classifier

Cancer vs. Dysplasia/Normal Training:

- 87,376 Normal/Dysplasia
- 1,399 Cancer



ROC for Dysplasia Cells vs. Normal/Cancer







DECEMBER 4-7, 2016 VIENNA, AUSTRIA

Case Level Outputs To Demonstrate LuCED Efficacy as a Liquid Biopsy

Degree of Histology (Snip

Cell Count	Normal Case	Dysplastic ^{Bio} Case - Mild	Dysplastic Case - Severe	Cancer Case
Normal	Н	М	Μ	Μ
Dysplasia	L	М	H	Μ
Cancer	L Tr	ajectory Unde	Moprost Ther	apy





IASLC 17TH WORLD CONFERENCE ON LUNG CANCER

DECEMBER 4-7, 2016 VIENNA, AUSTRIA


Clinical Deployment

Detection of Lung Cancer

- LuCED to process incidentally discovered nodules
- LuCED adjunct to LDCT to reduce false positives
- Primary screening ahead of LDCT ٠

Chemo-prevention Therapy

- Non-invasive detection of dysplasia ٠
 - Differential sensitivity to:
 - Normal cells
 - Cancer precursor cells
 - Malignant cells
- Verified through comparison with biopsy







IASLC 17TH WORLD CONFERENCE ON LUNG CANCER

DECEMBER 4-7, 2016 VIENNA, AUSTRIA

Summary

The Promise of Chemoprevention of Lung Cancer: Enabled Using LuCED to Detect Dysplasia Non-invasively